| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6113655 | Critical Reviews in Oncology/Hematology | 2014 | 15 Pages |
Abstract
Early assessment and management of TT-ID is essential to prevent the worsening of this side-effect, patients' hospitalization and dose reduction or oncological treatment discontinuation. Future research is needed to better understand the pathophysiological mechanisms of TT-ID and it should also be investigated whether a specific pharmacological and/or non pharmachological approach is indicated.
Related Topics
Health Sciences
Medicine and Dentistry
Hematology
Authors
M.A. Pessi, N. Zilembo, E.R. Haspinger, L. Molino, S. Di Cosimo, M. Garassino, C.I. Ripamonti,